Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation.

Cegelski L, Pinkner JS, Hammer ND, Cusumano CK, Hung CS, Chorell E, Aberg V, Walker JN, Seed PC, Almqvist F, Chapman MR, Hultgren SJ.

Nat Chem Biol. 2009 Dec;5(12):913-9. doi: 10.1038/nchembio.242. Epub 2009 Oct 25.

2.

Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice.

Guiton PS, Cusumano CK, Kline KA, Dodson KW, Han Z, Janetka JW, Henderson JP, Caparon MG, Hultgren SJ.

Antimicrob Agents Chemother. 2012 Sep;56(9):4738-45. doi: 10.1128/AAC.00447-12. Epub 2012 Jun 25.

3.

Modulation of curli assembly and pellicle biofilm formation by chemical and protein chaperones.

Andersson EK, Bengtsson C, Evans ML, Chorell E, Sellstedt M, Lindgren AE, Hufnagel DA, Bhattacharya M, Tessier PM, Wittung-Stafshede P, Almqvist F, Chapman MR.

Chem Biol. 2013 Oct 24;20(10):1245-54. doi: 10.1016/j.chembiol.2013.07.017. Epub 2013 Sep 12.

4.

Transposon mutagenesis identifies uropathogenic Escherichia coli biofilm factors.

Hadjifrangiskou M, Gu AP, Pinkner JS, Kostakioti M, Zhang EW, Greene SE, Hultgren SJ.

J Bacteriol. 2012 Nov;194(22):6195-205. doi: 10.1128/JB.01012-12. Epub 2012 Sep 14.

5.

Functional analysis of antigen 43 in uropathogenic Escherichia coli reveals a role in long-term persistence in the urinary tract.

Ulett GC, Valle J, Beloin C, Sherlock O, Ghigo JM, Schembri MA.

Infect Immun. 2007 Jul;75(7):3233-44. Epub 2007 Apr 9.

6.
7.

Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria.

Pinkner JS, Remaut H, Buelens F, Miller E, Aberg V, Pemberton N, Hedenström M, Larsson A, Seed P, Waksman G, Hultgren SJ, Almqvist F.

Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17897-902. Epub 2006 Nov 10.

8.

Suppression of type 1 pilus assembly in uropathogenic Escherichia coli by chemical inhibition of subunit polymerization.

Lo AW, Van de Water K, Gane PJ, Chan AW, Steadman D, Stevens K, Selwood DL, Waksman G, Remaut H.

J Antimicrob Chemother. 2014 Apr;69(4):1017-26. doi: 10.1093/jac/dkt467. Epub 2013 Dec 8.

9.

Community behavior and amyloid-associated phenotypes among a panel of uropathogenic E. coli.

Lim JY, Pinkner JS, Cegelski L.

Biochem Biophys Res Commun. 2014 Jan 10;443(2):345-50. doi: 10.1016/j.bbrc.2013.11.026. Epub 2013 Nov 15.

10.

Design and synthesis of fluorescent pilicides and curlicides: bioactive tools to study bacterial virulence mechanisms.

Chorell E, Pinkner JS, Bengtsson C, Edvinsson S, Cusumano CK, Rosenbaum E, Johansson LB, Hultgren SJ, Almqvist F.

Chemistry. 2012 Apr 10;18(15):4522-32. doi: 10.1002/chem.201103936. Epub 2012 Mar 16.

11.

Molecular characterization of UpaB and UpaC, two new autotransporter proteins of uropathogenic Escherichia coli CFT073.

Allsopp LP, Beloin C, Ulett GC, Valle J, Totsika M, Sherlock O, Ghigo JM, Schembri MA.

Infect Immun. 2012 Jan;80(1):321-32. doi: 10.1128/IAI.05322-11. Epub 2011 Sep 19.

12.

Biogenesis and adhesion of type 1 and P pili.

Lillington J, Geibel S, Waksman G.

Biochim Biophys Acta. 2014 Sep;1840(9):2783-93. doi: 10.1016/j.bbagen.2014.04.021. Epub 2014 May 2. Review.

PMID:
24797039
13.

Virulence and Fitness Determinants of Uropathogenic Escherichia coli.

Subashchandrabose S, Mobley HL.

Microbiol Spectr. 2015 Aug;3(4). doi: 10.1128/microbiolspec.UTI-0015-2012. Review.

14.

Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli.

Greene SE, Pinkner JS, Chorell E, Dodson KW, Shaffer CL, Conover MS, Livny J, Hadjifrangiskou M, Almqvist F, Hultgren SJ.

MBio. 2014 Oct 28;5(6):e02038. doi: 10.1128/mBio.02038-14.

15.

Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37.

Kai-Larsen Y, Lüthje P, Chromek M, Peters V, Wang X, Holm A, Kádas L, Hedlund KO, Johansson J, Chapman MR, Jacobson SH, Römling U, Agerberth B, Brauner A.

PLoS Pathog. 2010 Jul 22;6(7):e1001010. doi: 10.1371/journal.ppat.1001010.

16.

Adhesive fiber stratification in uropathogenic Escherichia coli biofilms unveils oxygen-mediated control of type 1 pili.

Floyd KA, Moore JL, Eberly AR, Good JA, Shaffer CL, Zaver H, Almqvist F, Skaar EP, Caprioli RM, Hadjifrangiskou M.

PLoS Pathog. 2015 Mar 4;11(3):e1004697. doi: 10.1371/journal.ppat.1004697. eCollection 2015 Mar.

17.

Characterisation of uropathogenic Escherichia coli from children with urinary tract infection in different countries.

Ramos NL, Dzung DT, Stopsack K, Jankó V, Pourshafie MR, Katouli M, Brauner A.

Eur J Clin Microbiol Infect Dis. 2011 Dec;30(12):1587-93. doi: 10.1007/s10096-011-1264-4. Epub 2011 Apr 21.

PMID:
21509475
18.

The repeat-in-toxin family member TosA mediates adherence of uropathogenic Escherichia coli and survival during bacteremia.

Vigil PD, Wiles TJ, Engstrom MD, Prasov L, Mulvey MA, Mobley HL.

Infect Immun. 2012 Feb;80(2):493-505. doi: 10.1128/IAI.05713-11. Epub 2011 Nov 14.

19.

Pilicides inhibit the FGL chaperone/usher assisted biogenesis of the Dr fimbrial polyadhesin from uropathogenic Escherichia coli.

Piatek R, Zalewska-Piatek B, Dzierzbicka K, Makowiec S, Pilipczuk J, Szemiako K, Cyranka-Czaja A, Wojciechowski M.

BMC Microbiol. 2013 Jun 12;13:131. doi: 10.1186/1471-2180-13-131.

20.

Fimbrial profiles predict virulence of uropathogenic Escherichia coli strains: contribution of ygi and yad fimbriae.

Spurbeck RR, Stapleton AE, Johnson JR, Walk ST, Hooton TM, Mobley HL.

Infect Immun. 2011 Dec;79(12):4753-63. doi: 10.1128/IAI.05621-11. Epub 2011 Sep 12.

Items per page

Supplemental Content

Write to the Help Desk